Special Issue

Recent Advances in Psychiatric Medications

Message from the Guest Editors

Today, psychiatric drugs are one of the most important treatment options for people suffering from mental health disorders. In fact, the introduction of psychiatric medications was one of the biggest breakthroughs in the history of the treatment of mental disorders. At the same time, there is still a need for further research into their application in areas that have so far received little coverage. The use of psychiatric drugs has also been criticized from a number of legitimate perspectives regarding their significant side effects, the potential abuse of certain substances, the related abandonment of other treatments (such as psychotherapy), or even the relegation of important individual and social problems to the simple and relatively inexpensive solution of taking a pill. This Special Issue aims to highlight cutting-edge research, innovative approaches, and emerging trends in the development, efficacy, safety, utilization, and limitations of psychiatric medications. I look forward to your valuable contributions.

Guest Editors

Dr. Przemyslaw Waszak

Department of Hygiene and Epidemiology, Medical University of Gdansk, Gdansk, Poland

Prof. Dr. Paweł Zagożdżon

Department of Hygiene and Epidemiology, Faculty of Medicine, Medical University of Gdansk, 80-210 Gdansk, Poland

Deadline for manuscript submissions

closed (25 May 2025)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/200626

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceutica

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

